Advertisement
Advertisement
U.S. Markets open in 2 hrs 54 mins
Advertisement
Advertisement
Advertisement
Advertisement

Tekla Life Sciences Investors (HQL)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
14.68-0.01 (-0.07%)
At close: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close14.69
Open14.86
Bid14.69 x 800
Ask15.15 x 800
Day's Range14.36 - 14.84
52 Week Range13.86 - 22.70
Volume115,595
Avg. Volume75,481
Market Cap362.132M
Beta (5Y Monthly)0.89
PE Ratio (TTM)5.61
EPS (TTM)2.62
Earnings DateN/A
Forward Dividend & Yield1.56 (10.83%)
Ex-Dividend DateFeb 24, 2022
1y Target EstN/A
  • Business Wire

    Tekla Life Sciences Investors Declares Distribution

    BOSTON, May 17, 2022--On May 17, 2022, Tekla Life Sciences Investors declared a distribution of $0.35 per share. The record date for the distribution is May 27, 2022 and the payable date is June 30, 2022. The Fund will trade ex-distribution on May 26, 2022.

  • Business Wire

    Tekla Life Sciences Investors Paid Distribution

    BOSTON, March 31, 2022--On March 31, 2022, Tekla Life Sciences Investors paid a distribution of $0.39 per share. It is currently estimated that this distribution is derived from net realized long-term capital gains and return of capital or other capital source. The composition of this and subsequent distributions may vary from quarter to quarter because it may be materially impacted by future realized gains and losses on securities. The aggregate of the net unrealized appreciation of portfolio s

  • Business Wire

    Tekla Life Sciences Investors Announce Renewal of Share Repurchase Program

    BOSTON, March 22, 2022--Tekla Life Sciences Investors (the "Fund") announced today that its Board of Trustees authorized a renewal of its share repurchase program. The current share repurchase program allows the Fund to purchase in the open market up to 12% of its outstanding common shares for a one-year period ending July 14, 2022. The renewal will allow the Fund to purchase in the open market up to 12% of its outstanding common shares for a one year-period ending July 14, 2023. The Board autho

Advertisement
Advertisement